Estévez, F. V. http://orcid.org/0000-0001-9336-3588
,
Alarcón, Mª D. L.
Mayoral, V.
de Madariaga, M.
Margarit, C.
Duran, J. A.
Martín-Arroyo, J. M. T.
Carregal, A.
Funding for this research was provided by:
Takeda pharmaceutics
Grupo de trabajo de dolor oncol?gico of the SED
Article History
Received: 26 September 2018
Accepted: 14 January 2019
First Online: 19 February 2019
Compliance with ethical standards
:
: The following authors declare potential conflicts of interest for individual activities for the industry: Villegas Estévez F. has received payments for consultancies and lecture fees from Kyowa kirin, Gebro pharma, Grünenthal, Ferrer and Mylan. López Alarcón M.D. has received payments for consultancies and lecture fees from Kyowa kirin, Takeda, Gebro pharma, Lab Esteve, Teva and Grünenthal. Mayoral V. has received payments for consultancies and lecture fees from Menarini, Pfizer, Grünenthal, Mundipharma, Takeda y Kyowa Kirin. Madariaga M. has received lecture fees from Kyowa kirin, Grünenthal, Mundipharma, Ferrer and Medtronic. Carregal A. has received payments for consultancies and lecture fees from Takeda, Gebro pharma, Lab Esteve, Teva, Grünenthal and Kyowa kirin. Trinidad Martín-Arroyo JM. has received payments for consultancies and lecture fees from Takeda, Gebro pharma, Lab Esteve, Teva, Grünenthal, and Kyowa kirin.
: This article does not contain any studies with human participants or animals performed by any of the authors.
: For this type of study formal consent is not required.